Industry

EMERYVILLE, Calif. & ALBANY, N.Y.–(BUSINESS WIRE)–#AMRI–Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, and Curia, formerly AMRI, a leading contract research, development and manufacturing organization (CDMO), today announced Curia’s adoption of The Beacon® Optofluidic system and workflows from Berkeley Lights to accelerate and expand its antibody-based drug discovery capabilities. The Beacon system … [Read more…]

In 67 ROS1 TKI-naïve patients, the confirmed objective response rate (cORR) and disease control rate (DCR) were 92.5% and 95.5%, respectively. In 38 crizotinib-pretreated patients, the cORR and DCR were 50% and 78.9%, respectively. In 12 patients with brain metastasis and measurable brain lesions at baseline, the intracranial cORR and intracranial DCR were 91.7% and … [Read more…]

SAN DIEGO–(BUSINESS WIRE)–​ Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the appointment of Janet Loesberg, Pharm. D., to its Board of Directors. “I am pleased to welcome Janet as the newest director to Ambrx’s Board,” … [Read more…]

Results show broad cardiometabolic health improvement, including blood sugar control, weight loss, and medication deprescription, with half of all diabetes drugs eliminated at 5 years “Through Virta, I not only reversed my diabetes and lost over 50 pounds, I got my life back.” — Jane Ann Dimitt, who lowered her A1c from 11.4% to 5.5% … [Read more…]

— In the United States, approximately 3 out of every 4 patients do not meet target LDL-c goals1; in Europe, about 4 out of every 5 patients in the highest risk group do not meet their target LDL-c goals2 — — 82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 … [Read more…]

SAN DIEGO–(BUSINESS WIRE)–IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced the appointment of John Huynh, Ph.D., as the Company’s first Chief Technology Officer. Dr. Huynh brings nearly two decades of experience leading and developing specialized manufacturing … [Read more…]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, today announced that Apnimed will participate in the Jefferies Healthcare Conference taking place June 8-10, 2022, and invites investors to view the live presentation and participate in one-on-one meetings. Please see additional details … [Read more…]

ADI-001 demonstrated 75% CR and ORR rate across all dose levels with favorable safety and tolerability profile in patients with relapsed/refractory high grade aggressive Non-Hodgkin’s Lymphoma (NHL), as of May 31, 2022 data-cut date 80% ORR and CR rate at dose levels 2 and 3 combined 100% ORR and CR rate in three anti-CD19 CAR-T … [Read more…]

Launch of Human FFPE Immuno-oncology Data Release represents largest public data set for single-cell spatial genomics ever released Oral and poster presentations highlight how MERSCOPE enables researchers to uncover new findings in the human tumor microenvironment as well as the mouse brain CAMBRIDGE, Mass.–(BUSINESS WIRE)–Vizgen, the life science company dedicated to improving human health by … [Read more…]

Interim Analysis Findings Support Continued Evaluation of Both Monotherapy and Combination Therapy Encouraging Efficacy Results Include Independently Confirmed Responses in Both KRAS Mutant and KRAS Wild-Type Tumors with No New Safety Signals Observed Substantial Majority (~80%) of Patients Remain on Therapy; Timing of Go Forward Treatment Regimen Selection Driven by Data Maturity BOSTON–(BUSINESS WIRE)–Verastem Oncology … [Read more…]